SGMT
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ: SGMT · HEALTHCARE · BIOTECHNOLOGY
$7.71
+0.92% today
Updated 2026-05-08
Market cap
$476.11M
P/E ratio
—
P/S ratio
52.50x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$3 – $11
Volume
1.6M
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-10.55M | $-10.42M | $-21.71M | $-24.49M | $-23.77M | $-42.44M | $-45.65M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $2.99M | $775000.00 | $1.90M | $1.88M | $4.99M | $5.29M | $6.45M |
| Free cash flow | $-10.55M | $-10.42M | $-21.71M | $-24.49M | $-23.77M | $-42.44M | $-45.65M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |